We are excited to introduce the Angiolutions Advisory Board! Each member brings a wealth of knowledge and experience to our mission of delivering the first implant designed to treat abdominal aortic aneurysms at an early stage. Meet our board members: Ruti Alon, Prof. Lars Maegdefessel, Eileen Rose, Prof. Dr. med. Hubert Schelzig, Dr. Hannah Teichmann, Prof. Phil Tsao Get to know the board members at: https://lnkd.in/dBCuxvx5 The picture shows our board and leadership team at a recent meeting in Germany.
Info
Angiolutions – breaking new ground in abdominal aortic aneurysm (AAA) treatment. Abdominal aortic aneurysms are threatening the lives of millions of patients around the world with no way to intercept early disease progression. Angiolutions will change that. Angiolutions is the first company to develop a therapeutic device preventing disease progression in small abdominal aortic aneurysms.
- Website
-
https://www.angiolutions.com
Externer Link zu Angiolutions
- Branche
- Herstellung medizinischer Geräte
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Hannover
- Art
- Privatunternehmen
Orte
-
Primär
Wegbeschreibung
Vahrenwalder Str. 269A
Hannover, 30179, DE
Beschäftigte von Angiolutions
Updates
-
What makes aneurysms grow and how can we stop them early? Very interesting presentation from Priv.- Doz. Dr. med. Markus Wagenhäuser – thanks for mentioning us in your post!
In recent years, we have significantly advanced our understanding of aneurysm growth, particularly with regard to the critical role of aortic stiffness. I was pleased to present my work, titled "The Concept of Segmental Aortic Stiffness - An Idea from Bench to Bedside," at the 52nd Annual Meeting of the Japanese Society for Vascular Surgery in Beppu, Japan, last month. I am encouraged by the rapid progress of translating the concept of aortic stiffness from research to clinical application. #Angiolutions is currently developing an implant that targets this primary driver of aneurysm growth, enabling early-stage treatment of abdominal aortic aneurysms for the first time.
-
-
This week, we have something to celebrate: Angiolutions won first prize at the START HEALTHCARE startup competition at #MedtecLIVE! The journey as a #MedTech startup is full of challenges – receiving this endorsement strengthens us on our mission to bring the first early-stage treatment to stop abdominal aortic aneurysms to patients! A big thank you to Medical Valley EMN e. V., Kurt Höller, Flying Health, gesundheit.digital.forum, MedtecLIVE and the jury members Alexander Rehn, Gerhard Lesch, Marco Wendel, Ann-Kathrin von Knobloch (Weigand), Matthias Schwarz, Christian Dorn and Jan Engels!
-
-
Next week, we'll be at the HTGF Family Day 2024! Our CEO and co-founder Isabel N. Schellinger and our CBO Marius Rummel, are looking forward to insightful conversations and discovering new opportunities together with you. Find out more at: https://lnkd.in/eY7nNXt HTGF | High-Tech Gründerfonds
-
-
You just got a “new” organ… the aorta! We are excited that the largest blood vessel in your body has been recognized as an organ in the latest medical guidelines. This means more attention to aortic diseases and better future treatment for patients, for example for people suffering from the most common aortic disease: abdominal aortic aneurysm (AAA). AAA is threatening the lives of millions of patients around the world with no way to intercept the disease early. At Angiolutions, we are dedicated to transforming aortic disease treatment with our unique implant to stop AAA already at an early stage. Full new guidelines: https://lnkd.in/d6XmgqSa
-
-
Is it time for cardiologists to evolve into “clinician-scientist-entrepreneurs”? Join our co-founder, Uwe Raaz, along with a panel of entrepreneurs and experts to explore this intriguing question at the annual meeting of the German Society of Cardiology! #dgk Herzmedizin.de, Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V.
Klinik – Wissenschaft – und jetzt auch noch gründen? Klingt spannend, aber wie kann das eigene Start-up in der Kardiologie Realität werden? Kann so der Innovationstransfer aus der Forschung zum Patienten und in die Gesellschaft besser gelingen? Wir freuen uns, mit Ihnen zu diskutieren!
Dieser Inhalt ist hier nicht verfügbar.
Mit der LinkedIn App können Sie auf diese und weitere Inhalte zugreifen.
-
Angiolutions hat dies direkt geteilt
Diesen Freitag und Samstag präsentiert MeKo im Rahmen der Leibniz #UniverCity gemeinsam mit der Fakultät für Maschinenbau der Leibniz Universität Hannover spannende Experimente aus der #Medizintechnik. Veranstaltungsort ist der #aufhof in #Hannover. Das Angebot richtet sich an Schülerinnen und Schüler, Studierende und interessierte Erwachsene. Der Eintritt ist frei. Am Freitagnachmittag findet im dortigen Auditorium von 16:15 bis 17:00 Uhr die #Podiumsdiskussion "Engineering Body Parts: Technologien für den Körpereinsatz" statt - mit MeKo-Geschäftsführer Jakob Dohse und Uwe Raaz, dem Gründer und Geschäftsführer von Angiolutions.
-
-
Will you be at the Medica next week? Our Chief Business Officer, Marius Rummel will be at the fair and is looking forward to meeting you.
-
-
“How can science become medicine?“ will be the topic of our short presentation at the “Future Medicine Science Match 2023”. Our Chief Business Officer, Marius Rummel, is looking forward to meeting you at this exciting event by Verlag Der Tagesspiegel and Berlin Institute of Health. Official website: https://lnkd.in/eiGnFvYr
-